Using the 6-min Walk Test to Monitor Peak Oxygen Uptake Response to Cardiac Rehabilitation in Patients With Heart Failure

Chirico, Daniele; Davidson, Travis; Terada, Tasuku; Scott, Kyle; Keast, Marja-Leena; Reid, Robert D.; Pipe, Andrew; Reed, Jennifer L.

doi:10.1097/hcr.0000000000000517

Cited by 9 publications

(9 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The 6MWT has long been used in cardiac and pulmonary rehabilitation as an objective assessment of the physical capacity of patients and the effects of treatment, including training programs [ 34 , 35 ]. The test has also been used to study pts after contracting COVID-19 [ 36 , 37 ].…”

Section: Discussionmentioning

confidence: 99%

Use of 1-MNA to Improve Exercise Tolerance and Fatigue in Patients after COVID-19

Chudzik¹,

Burzyńska

Kapusta

2022

Nutrients

View full text Add to dashboard Cite

COVID-19 is not only a short-term infection, as patients (pts) recovering from SARS-CoV-2 infection complain of persisting symptoms, which may lead to chronic fatigue syndrome. There is currently no evidence that nutritional supplements can assist in the recovery of pts with chronic fatigue syndrome. 1-Methylnicotinamide (1-MNA) is an endogenic substance that is produced in the liver when nicotinic acid is metabolized. 1-MNA demonstrates anti-inflammatory and anti-thrombotic properties. Therefore, we investigated whether 1-MNA supplements could improve exercise tolerance and decrease fatigue among patients recovering from SARS-CoV-2. Methods: The study population was composed of 50 pts who had recovered from symptomatic COVID-19. The selected pts were randomized into two groups: Gr 1 (NO-1-MNA)—without supplementation; Gr 2 (1-MNA) with 1-MNA supplementation. At the beginning of the study (Phase 0), in both groups, a 6-minute walk test (6MWT) was carried out and fatigue assessment was performed using the Fatigue Severity Scale (FSS). Both FSS and 6MWT were repeated after 1 month. Results: A significant improvement in the mean distance covered in the 6MWT was noted at follow-up in Gr 1-MNA, compared with Gr NO-1-MNA. We also noted that in Gr 1-MNA, the 6MWT distance was significantly higher after 1 month of supplementation with 1-MNA, compared with the beginning of the study (515.18 m in Phase 0 vs. 557.8 m in Phase 1; p = 0.000034). In Gr 1-MNA, significantly more pts improved their distance in the 6MWT (23 out of 25 pts, equal to 92%), by a mean of 47 m, compared with Gr NO-1-MNA (15 of 25 pts, equal to 60%) (p = 0.0061). After one month, significantly more patients in the group without 1-MNA had severe fatigue (FSS ≥ 4) compared with the group with supplementation (Gr 1-MNA = 5 pts (20%) vs. Gr NO-1-MNA = 14pts (56%); p = 0.008). Conclusions: 1-MNA supplementation significantly improved physical performance in a 6-min walk test and reduced the percentage of patients with severe fatigue after COVID-19. The comprehensive action of 1-MNA, including anti-inflammatory and anticoagulant effects, may be beneficial for the recovery of patients with persistent symptoms of fatigue and low tolerance to exercise after COVID-19.

show abstract

Section: Discussionmentioning

confidence: 99%

Use of 1-MNA to Improve Exercise Tolerance and Fatigue in Patients after COVID-19

Chudzik¹,

Burzyńska

Kapusta

2022

Nutrients

View full text Add to dashboard Cite

show abstract

“…The 6MWT has long been used in cardiac and pulmonary rehabilitation as an objective assessment of the physical capacity of patients and the effects of treatment, including training programs [35,36]. The test has also been used to study pts after contracting COVID-19 [37.38].…”

Section: Discussionmentioning

confidence: 99%

Use of 1-MNA to Improve Exercise Tolerance and Fatigue in Patients After COVID-19

Chudzik¹,

Kapusta

Burzyńska

2021

Preprint

View full text Add to dashboard Cite

Background: Coronavirus disease 2019 (COVID-19) is a serious respiratory disease that results from infection with a newly discovered coronavirus (SARS-COV-2). Unfortunately, COVID-19 is not only a short-term infection but that patients (pts) recovering from SARS-CoV2 infection complain of persisting symptoms including: fatigue, diffuse myalgia and weakness, which may lead to chronic fatigue syndrome. There is currently no evidence that nutritional supplements and/or physical exercise can assist in the recovery of pts with chronic fatigue syndrome. 1-Methylnicotinamide (1-MNA) is an endogenic substance that is produced in the liver when nicotinic acid is metabolized. 1-MNA demonstrates anti-inflammatory and anti-thrombotic properties. Therefore, we investigated whether 1-MNA supplements could improve exercise tolerance and decrease fatigue among patients recovering from SARS-CoV-2. Methods: The study population was composed of pts after COVID-19, expressing subjective feelings of limited tolerance to exercise. The selected pts were randomized into two groups: GrM0 without supplementation; GrM1 with 1-MNA supplementation. At the beginning of the study (Phase 0), in both groups, a 6-minute walk test (6MWT) was carried out and fa-tigue assessment with Fatigue Severity Scale (FSS) was performed. After 1 month (Phase 1), a follow up FSS and 6MWT once more were performed in both groups. Results: A significant improvement in the mean distance covered in the 6MWT was noted among the pts in GrM1, compared to those in GrM0. We also noted that in GrM1 the 6MWT distance was significantly higher after 1 month of supplementation with 1-MNA, compared to the beginning of the study (515.18 m in Phase 0 vs 557.8m in Phase 1; p = 0.000034). In GrM1, significantly more pts improved their distance in the 6MWT (23 out of 25 pts, equal to 92%), by a mean of 47 meters, compared to GrM0 (15 of 25 pts, equal to 60%) (p = 0.0061). After one month, significantly more patients in the group without 1-MNA had severe fatigue (FSS ≥ 4) compared to the group with supplementation (GrM1 = 5 pts (20%) vs GrM0 = 14pts (56%); p = 0.008). Conclusions: 1-MNA supplementation significantly improved physical performance in a 6-minute walk test and reduced the percentage of patients with severe fatigue after COVID-19. The comprehensive action of 1-MNA, including anti-inflammatory and anticoagulant effects, as well as activation of the SIRT1 enzyme, may be beneficial for the recovery of patients with persistent symptoms of fatigue and low tolerance to exercise after COVID-19. Keywords: COVID-19, MNA, chronic fatigue syndrome, post-COVID syndrome

show abstract

“…Pulmonary function was analyzed using SentrySuite software V03.0.5 (Vyaire Medical). The 6-min walking test (6MWT) was evaluated according to ATS/ERS guidelines ( 23 ).…”

Section: Methodsmentioning

confidence: 99%

Influence of transitional care on the clinical manifestations among patients with COVID‑19: A single‑center, double‑blinded, randomized survey

Sun

et al. 2022

Exp Ther Med

View full text Add to dashboard Cite

Pneumonia and acute respiratory distress syndrome are the major complications of coronavirus disease 2019 . Transitional care is indispensable in successfully transitioning patients with COVID-19 from hospital to home and preventing adverse events of this disease. The purpose of the present study was to analyze the effects of transitional care on improvements in inflammation and pulmonary function in patients with COVID-19. Data of all hospitalized patients with COVID-19 (n=242) discharged from Mudanjiang Medical University (Mudanjiang, China) between May 2020 and October 2020 were retrospectively collected. Patients with COVID-19 had been hospitalized and assigned to receive transitional care (n=126) or usual care (n=116) and were followed up for 12 months. Hospital stay, inflammation and pulmonary function were compared in patients with COVID-19 between the transitional care and usual care group. Transitional care significantly improved physical symptoms, anxiety, depression and empathy of the patients for other patients affected. Compared to the usual care group, marked improvements in typical symptoms, including dyspnea, asthenia, cough, nausea, chest pain, myalgia, headache, fever, diarrhea, chest pain, dizziness, conjunctivitis, as well as disorders of smell and taste, were observed in the transitional care group. Patients in the transitional care group had a shorter hospital stay than those patients in the usual care group. Furthermore, transitional care decreased inflammation and ameliorated pulmonary function in patients with COVID-19. In conclusion, transitional care has an essential role in the improvement of physical symptoms, inflammation and pulmonary function in patients with COVID-19 [Chinese Clinical Trial Registry (ChiCTR) registration no. ChiCTR2200060295; 26.05.2022].

show abstract

Using the 6-min Walk Test to Monitor Peak Oxygen Uptake Response to Cardiac Rehabilitation in Patients With Heart Failure

Abstract: Supplemental Digital Content is Available in the Text. Estimated peak oxygen uptake ( ) using 6-min Walk Test distance demonstrated poor agreement with measured from a cardiopulmonary exercise test in patients with heart failure enrolled in cardiac rehabilitation.

Cited by 9 publications

References 18 publications

Use of 1-MNA to Improve Exercise Tolerance and Fatigue in Patients after COVID-19

Use of 1-MNA to Improve Exercise Tolerance and Fatigue in Patients after COVID-19

Use of 1-MNA to Improve Exercise Tolerance and Fatigue in Patients After COVID-19

Influence of transitional care on the clinical manifestations among patients with COVID‑19: A single‑center, double‑blinded, randomized survey

Contact Info

Product

Resources

About